All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Mara Antonoff, MD
Disclosure(s): BMS, AZ, Merck, Ethicon: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

Jessica Donington, MD
Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

Team 1

Drew Moghanaki, MD, MPH
Disclosure(s): Astra Zenica: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Varian Medical Systems: Speaker (Ongoing)

Karen Reckamp, MD
Disclosure(s): AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, Genentech, GlaxoSmithKline, Janssen, Lilly, Mirati, Novartis, Novocure: Consultant (Terminated, September 11, 2024); Genentech; Blueprint; Daiichi Sankyo; Elevation Oncology; Janssen: research funding to institution (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Dan Raz, MD, MAS
Disclosure(s): Genentech: Advisory Board (Ongoing)

David Cooke, MD
Disclosure(s): Bristol Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive Surgical: In kind education support; Food (Ongoing); Oxford University Press: Royalties (Ongoing)

Team 2

Percy Lee, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Consultant (Ongoing); ImmuneSensor: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing); Roche: Consultant (Ongoing); RTOG Foundation: Consultant (Terminated); Varian: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Amy Cummings, MD, PhD
Disclosure(s): Astra Zeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); OncoHost: Consultant (Ongoing), Speaker (Ongoing); Tempus: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing)

Kiran Lagisetty, MD
Disclosure(s): AtriCure: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Loretta Erhunmwunsee, MD
Disclosure(s): Astrazeneca: Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker (Ongoing); Bristol Myers Squibb Foundation: Advisory Board (Ongoing)

Presentations

1. Introduction
2. Debate 1: Stage I - Wedge vs. SBRT
3. Debate 2: Stage II - Upfront Surgery and Adjuvant Therapy vs. Neoadjuvant Therapy and Surgery for cII NSCLC
4. Debate 3: Stage III -  Definitive Chemoradiation and Immunotherapy vs. Neoadjuvant Therapy and Surgery for Stage III
5. Debate 4: Stage IV - LCT vs. No LCT for Stage IV Oligometastatic on TKI